Repligen Corp(RGEN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 26 at 4:00 PM ET (Korea 10/27 05:00)
Full metrics table
| Index | - | P/E | 245.26 | EPS (ttm) | 0.73 | Insider Own | 5.56% | Shs Outstand | 63.5M | Perf Week | 2% |
| Market Cap | 11.43B | Forward P/E | 67.86 | EPS next Y | 28.74% | Insider Trans | -0.94% | Shs Float | 60.0M | Perf Month | -5.13% |
| Enterprise Value | 11.31B | PEG | 2.54 | EPS next Q | 0.46 | Inst Own | 111.73% | Short Float | 12.64% | Perf Quarter | 23.81% |
| Income | 0.04B | P/S | 14.55 | EPS this Y | 20.46% | Inst Trans | 5.17% | Short Ratio | 6.63 | Perf Half Y | 52.13% |
| Sales | 0.79B | P/B | 4.81 | EPS next 5Y | 26.72% | ROA | 1.42% | Short Interest | 7.58M | Perf YTD | 9.82% |
| Book/sh | 37.43 | P/C | 14.1 | EPS past 3/5Y | -35.6% -4.91% | ROE | 1.99% | 52W High | -9.51% ($198.87) | Perf Year | 8.19% |
| Cash/sh | 12.77 | P/FCF | 103.72 | Sales past 3/5Y | -2.7% 15.05% | ROIC | 1.49% | 52W Low | 78.19% ($100.99) | Perf 3Y | 46.9% |
| Dividend Est. | - | EV/EBITDA | 63.19 | EPS Y/Y TTM | 397.9% | Gross Margin | 48.79% | Volatility(W/M) | 4.12% 5.11% | Perf 5Y | -34.28% |
| Dividend TTM | - | EV/Sales | 14.4 | Sales Y/Y TTM | 16.49% | Oper. Margin | 9.03% | ATR (14) | 8.14 | Perf 10Y | 524.39% |
| Dividend Ex-Date | - | Quick Ratio | 7.64 | EPS Q/Q | -66.4% | Profit Margin | 5.29% | RSI (14) | 52.28 | Recom | 1.55 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.05 | Sales Q/Q | 11.93% | SMA20 | 0.77% ($178.57) | Beta | 1.11 | Target Price | $202.28 |
| Payout | - | Debt/Eq | 0.33 | Earnings | 2026/10/27 | SMA50 | 1.46% ($177.36) | Rel Volume | 1.03 | Prev Close | $176.93 |
| Employees | 2000 | LT Debt/Eq | 0.32 | EPS/Sales Surpr. | 20.81% 1.26% | SMA200 | 24.57% ($144.46) | Avg Volume(3M) | 1.14M | Price | $179.95 |
| IPO | 1986/4/29 | Option/Short | Yes/Yes | Trades | 19322 | Volume | 1,176,991 | Change | 1.71% |
🧪 A U.S. life sciences company that supplies process technologies and consumables used in biopharmaceutical production. It provides filtration, purification, analytics, and fluid management solutions needed to manufacture biopharmaceuticals such as antibodies, cell therapies, and gene therapies, positioning it as a medical tools play whose performance is tied to biomanufacturing demand and the expansion of new drug pipelines.
Over the past 1 year, on the higher side
10% below its 1-year high.
Traded about as much as usual. That is 103% of its average volume.
Next earnings report: October 27
1 days to go.
RGEN earns at a steady pace
Of every $100 in sales, $9.03 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +20.5% this year.
Tap to view numbers
However, it looks expensive
For a company expected to earn $100 next year, you would pay $6,786. Peers typically go for $1,968. Compared with its own 5-year average, it is 81% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -34.3%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 111.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
FBT First Trust NYSE Arca Biotechnology Index Fund 0.03% 
PBE Invesco Biotechnology & Genome ETF 0.03% 
FRTY Alger Mid Cap 40 ETF 0.03% 
CSMD Congress SMid Growth ETF 0.03% 
TFGZ Thornburg Focus Growth Fund 0.03% Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
ARGT Global X MSCI Argentina ETF 685M It ranks #11 of 51 in the industry
Based on market cap of $11B.
BAX#8 Baxter International Inc $13B PER - 
AVTR#9 Avantor Inc $12B PER - 
COO#10 Cooper Companies Inc $12B PER 20.9 RGEN#11 Repligen Corp $11B PER 245.3 
ALGN#12 Align Technology Inc $11B PER 26.4 
FAQ
What kind of company is RGEN?
RGEN belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is the market cap of RGEN?
The market cap of RGEN is approximately $11.4B, ranking 836 within its sector.
What is the P/E ratio of RGEN?
RGEN has a P/E ratio of approximately 245.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for RGEN?
RGEN has recorded a 52-week high of $198.87 and a low of $100.99.
